Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study

Background: Persons with neuroinflammatory diseases (pwNID) treated with potent immunosuppressives are at risk of severe COVID-19 outcomes and reduced vaccine seroconversion. We aimed at determining the real-world efficacy of tixagevimab and cilgavimab (Evusheld™) in immunosuppressed pwNID in preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakimovski, Dejan, Eckert, Svetlana P., Mirmosayyeb, Omid, Thapa, Sangharsha, Pennington, Penny, Hojnacki, David, Weinstock-Guttman, Bianca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963629/
https://www.ncbi.nlm.nih.gov/pubmed/36851227
http://dx.doi.org/10.3390/vaccines11020350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963629/
https://www.ncbi.nlm.nih.gov/pubmed/36851227
http://dx.doi.org/10.3390/vaccines11020350

Ejemplares similares